Next-generation Sequencing Market Size & Growth Forecast 2027–2036, By Segments (Workflow, Technology, End-use, Application, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Next-generation Sequencing Market size was estimated at USD 13.3 billion in 2026 and is projected to grow at a 17.1% CAGR from 2027 to 2036, attaining USD 64.48 billion by 2036. The industry revenue for 2027 is calculated at USD 15.22 billion.
Get more details on this report
Request Free Sample ReportNext-generation Sequencing Market Intelligence Snapshot
Regional Market Dynamics
- North America led the market in 2026 due to its advanced genomics laboratories, established clinical testing infrastructure, and widespread sequencing adoption across research, diagnostics, and precision medicine.
- Asia Pacific is projected to grow at a 23.43% CAGR, supported by expanding genomic testing infrastructure, broader sequencing adoption, and increasing use in clinical research and disease profiling.
Segment Momentum
- Sequencing held a 62.38% share in 2026 because it is the core step that generates genomic data, with throughput, data quality, and instrument utilization directly influencing workflow efficiency and project output.
- Whole Exome Sequencing is growing rapidly because it provides broader variant detection than targeted methods while remaining more manageable than whole genome sequencing, balancing discovery potential with operational efficiency.
Market Expansion Drivers
- Rising adoption of NGS in oncology and clinical diagnostics accelerating genomic testing demand.
- Continuous advancements in sequencing platforms improving throughput, accuracy, and cost efficiency.
- Expanding precision medicine and population genomics programs increasing large-scale sequencing utilization.
Leading Market Participants
- Major players in the next-generation sequencing market include Illumina, Inc. (United States), Thermo Fisher Scientific Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Pacific Biosciences of California, Inc. (United States), Oxford Nanopore Technologies plc (United Kingdom), BGI Genomics Co., Ltd. (China), Bio-Rad Laboratories, Inc. (United States), Merck KGaA (Germany), Revvity, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 13.3 billion
- 2027 Estimated Market Size: USD 15.22 billion.
- Projected Market Size: USD 64.48 billion by 2036
- Growth Forecast: 17.1% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Sequencing (Workflow) | Targeted Sequencing & Resequencing (Technology) | Academic Research (End-use) | Oncology (Application) | Consumables (Product)
- Emerging Opportunity Segment: Sequencing (Workflow) | Whole Exome Sequencing (Technology) | Clinical Research (End-use) | Consumer Genomics (Application) | Consumables (Product)
Market Growth Drivers and Industry Trends
Rising adoption of NGS in oncology and clinical diagnostics accelerating genomic testing demand
Rising adoption of NGS in oncology and clinical diagnostics will drive the next-generation sequencing market growth by enabling more comprehensive analysis of genetic information for disease identification and treatment decisions. In oncology, sequencing can help characterize tumor-specific genomic alterations, while clinical applications can support the investigation of inherited and acquired conditions. The increasing integration of genomic testing into diagnostic workflows is creating demand for sequencing platforms, consumables, and associated analytical capabilities that can process complex genetic information.
Continuous advancements in sequencing platforms improving throughput, accuracy, and cost efficiency
Continuous advancements in sequencing platforms will propel the next-generation sequencing market growth by improving the ability of laboratories and research organizations to process larger volumes of genetic information with greater efficiency. Enhancements in sequencing technologies can increase throughput while improving analytical accuracy and reducing the resources required for genomic analysis. Better performance and cost efficiency can also make sequencing more practical for routine laboratory applications and broader clinical use, supporting adoption among organizations with diverse testing requirements.
Expanding precision medicine and population genomics programs increasing large-scale sequencing utilization
Expanding precision medicine and population genomics programs will boost the next-generation sequencing market demand by increasing the need to analyze genetic information across individual patients and broader population groups. Precision medicine initiatives rely on genomic data to support more tailored approaches to disease management, while population genomics programs require sequencing capabilities that can accommodate large and diverse datasets. The resulting demand extends across sequencing instruments, consumables, sample processing, and genomic data analysis workflows.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising adoption of NGS in oncology and clinical diagnostics accelerating genomic testing demand | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Continuous advancements in sequencing platforms improving throughput, accuracy, and cost efficiency | 1.90% | Moderate | North America, Europe | High | Mid Term |
| Expanding precision medicine and population genomics programs increasing large-scale sequencing utilization | 1.70% | High | Asia Pacific, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The next-generation sequencing market was led by North America, which held the largest share in 2026, supported by advanced genomic research infrastructure, strong adoption of precision medicine, and extensive sequencing activity across clinical, pharmaceutical, and academic applications. The region benefits from well-established healthcare systems and continued investment in genomic technologies, enabling broader use of sequencing for disease diagnosis, biomarker discovery, oncology research, and personalized treatment strategies. The integration of sequencing with bioinformatics, artificial intelligence, and cloud-based data analysis is further improving the ability of healthcare and research institutions to manage complex genomic datasets. In addition, growing clinical adoption of molecular diagnostics and the expansion of genomic testing are reinforcing regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is positioned as the fastest-growing region, driven by expanding healthcare infrastructure, increasing investments in biotechnology and genomics, and rising awareness of advanced molecular diagnostics. Countries across the region are strengthening genomic research capabilities and incorporating sequencing technologies into areas such as cancer screening, inherited disease testing, infectious disease surveillance, and agricultural research. Greater availability of sequencing services, improving access to advanced laboratory technologies, and growing public and private support for precision healthcare are broadening the addressable market. The region's large and diverse patient population also creates substantial opportunities for genomic studies and the development of population-specific healthcare applications.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Translational Research FocusGermany integrates next-generation sequencing into biomedical research and clinical diagnostics through strong collaboration between healthcare institutions and research organizations. Investment remains focused on improving genomic workflows and expanding precision healthcare applications.
France 🇫🇷
Public Health GenomicsFrance advances next-generation sequencing through national healthcare initiatives and expanding genomic research programs. Clinical laboratories increasingly integrate sequencing technologies to improve disease characterization and support evidence-based treatment planning.
Italy 🇮🇹
Laboratory ModernizationItaly is strengthening next-generation sequencing adoption by modernizing diagnostic laboratories and expanding genomic testing capacity. Healthcare institutions focus on improving workflow efficiency and integrating sequencing into routine clinical and research applications.
Japan 🇯🇵
Precision Diagnostics IntegrationJapan is incorporating next-generation sequencing into oncology, rare disease research, and clinical laboratory services. Healthcare providers emphasize standardized genomic testing and efficient analytical workflows to support personalized patient management.
South Korea 🇰🇷
Genomic Innovation EcosystemSouth Korea continues expanding next-generation sequencing capabilities through biotechnology innovation and advanced healthcare initiatives. The country supports wider genomic analysis across research, diagnostics, and precision medicine programs to strengthen clinical decision-making.
United States 🇺🇸
Clinical Genomics ExpansionThe U.S. next-generation sequencing market benefits from broad clinical adoption, precision medicine initiatives, and active genomics research. Healthcare providers and research institutions continue expanding sequencing applications to improve diagnostic capabilities and personalized treatment strategies.
Segment Leadership and Growth Trends
Next-generation Sequencing Market Share (%), by Workflow, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWorkflow Segment Analysis: Sequencing (Largest & Fastest-Growing Segment)
Sequencing dominated the next-generation sequencing market with a 62.38% share in 2026 and also represented the fastest-growing workflow segment. As the core stage through which genetic information is generated and analyzed, sequencing remains central to applications spanning genomic research, molecular diagnostics, precision medicine, and biological discovery. Increasing demand for comprehensive genomic information, together with continued improvements in sequencing accuracy, throughput, and workflow efficiency, is supporting sustained adoption. The expanding role of genomic analysis in disease research and personalized healthcare further reinforces the importance of sequencing within the overall workflow.
Technology Segment Analysis: Targeted Sequencing & Resequencing (Largest Segment) vs Whole Exome Sequencing (Fastest-Growing Segment)
Targeted sequencing & resequencing accounted for 51.22% share in 2026, giving it the leading position within the technology segment of the next-generation sequencing market. Its adoption is supported by the ability to focus sequencing efforts on selected genomic regions, making it useful when researchers and healthcare providers require efficient analysis of specific genes or known areas of interest. Targeted approaches can also support streamlined workflows and focused investigation of clinically relevant genetic variations, contributing to their continued use across research and diagnostic settings.
Whole exome sequencing is the fastest-growing technology segment, benefiting from its ability to examine protein-coding regions across the genome and identify a broad range of genetic variants. Its expanding relevance in rare disease research, inherited disorder investigations, and precision medicine is increasing demand for more comprehensive genomic assessment. As healthcare and research applications place greater emphasis on uncovering complex genetic causes, whole exome sequencing provides a valuable balance between broad variant discovery and focused genomic analysis, supporting its accelerating adoption.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Workflow | Pre-Sequencing, Sequencing, NGS Data Analysis | Sequencing | Sequencing |
| Technology | WGS, Whole Exome Sequencing, Targeted Sequencing & Resequencing, Others | Targeted Sequencing & Resequencing | Whole Exome Sequencing |
| End-use | Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, Others | Academic Research | Clinical Research |
| Application | Oncology, Clinical Investigation, Reproductive Health, HLA Typing/Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Agrigenomics & Forensics, Consumer Genomics | Oncology | Consumer Genomics |
| Product | Platform, Consumables | Consumables | Consumables |
Competitive Landscape and Market Positioning
Prominent players in the next-generation sequencing market:
1. Illumina Inc. (United States)
2. Thermo Fisher Scientific Inc. (United States)
3. F. Hoffmann-La Roche Ltd. (Switzerland)
4. QIAGEN N.V. (Netherlands)
5. Pacific Biosciences of California Inc. (United States)
6. Oxford Nanopore Technologies plc (United Kingdom)
7. BGI Genomics Co. Ltd. (China)
8. Bio-Rad Laboratories Inc. (United States)
9. Merck KGaA (Germany)
10. Revvity Inc. (United States)
The next-generation sequencing market is evolving through advanced genomic technologies that enable faster and more accurate DNA sequencing. Continuous innovation is improving sequencing speed and data accuracy. Collaborative research initiatives are accelerating genomic discovery, while new sequencing platforms are expanding applications in precision medicine.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Illumina Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Pacific Biosciences of California Inc. (United States) | |||||||
| Oxford Nanopore Technologies plc (United Kingdom) | |||||||
| BGI Genomics Co. Ltd. (China) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Merck KGaA (Germany) | |||||||
| Revvity Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Illumina | May-26 | Illumina launched the Billion Cell Atlas, an expansive disease biology data framework designed to support target identification and AI-driven drug discovery applications. The commercial launch expands the ecosystem utility of high-throughput sequencing data by linking advanced genomic analysis directly to precision medicine pipelines. |
| Integrated DNA Technologies (IDT) | Mar-26 | Integrated DNA Technologies introduced new in vitro diagnostic assay kits based on its proprietary Anchored Multiplex PCR chemistry. The product launch delivers standardized, targeted DNA and RNA sequencing workflows optimized for oncology diagnostics, reducing clinical testing complexity and supporting broader laboratory adoption. |
| Oxford Gene Technology (OGT) | Nov-25 | Oxford Gene Technology expanded its minimal residual disease portfolio with the launch of the SureSeq Myeloid MRD Plus NGS Panel. The specialized panel integrates with the company's Interpret software platform, improving workflow efficiency, analytical reproducibility, and lower limits of detection for clinical laboratories. |
| Avance Biosciences | Jul-25 | Avance Biosciences established its Next-Generation Sequencing Center of Excellence in Houston, expanding its domestic sequencing capacity. The specialized facility strengthens the company's operational infrastructure to support advanced genomic testing, high-throughput workflows, and large-scale contract research capabilities required for commercial drug development programs. |
| VieCure | Jul-25 | VieCure entered into a strategic partnership with Guardant Health to integrate liquid and tissue-based genomic diagnostics into real-time oncology workflows. The collaboration drives technology adoption by connecting advanced next-generation sequencing diagnostics with AI-enabled clinical decision support systems at the point of care. |
| QIAGEN | Jul-25 | QIAGEN expanded its international market footprint through the launch of QIAseq xHYB Long-Read Panels in India. The product introduction optimizes target enrichment capabilities for long-read sequencing applications, directly supporting regional clinical and translational research in oncology and genetic disorders. |
| bioMérieux | Jun-25 | bioMérieux agreed to acquire the assets of Day Zero Diagnostics to enhance its capabilities in next-generation sequencing and rapid infectious disease diagnostics. This acquisition integrates advanced genomic technologies into bioMérieux's molecular diagnostics portfolio, accelerating the clinical commercialization of high-speed sequencing workflows for pathogen identification and resistance profiling. |
| Azenta | May-24 | Azenta expanded its international genomic services infrastructure through the opening of a new laboratory facility in Oxford, United Kingdom. The geographic expansion increases localized capacity for next-generation sequencing services and provides region-specific sample collection infrastructure to support clinical and academic workflows. |
| Oxford Nanopore Technologies | Mar-24 | Oxford Nanopore Technologies partnered with SeqOne to develop an end-to-end clinical diagnostics platform for rare diseases using long-read nanopore sequencing for whole-genome analysis. The collaborative initiative establishes a high-resolution workflow with planned future commercial expansion into oncology testing segments. |
| Quest Diagnostics | Jan-24 | Quest Diagnostics established a strategic partnership with Ultima Genomics to deploy Ultima's high-throughput next-generation sequencing architecture across its clinical testing operations. The initiative focuses on oncology diagnostics and diverse disease areas, scaling advanced genomic capabilities across an expansive laboratory network. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Next-generation Sequencing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | DNA Samples, RNA Samples, Cell-Free Nucleic Acids, FFPE & Tissue Samples, Microbial & Environmental Samples |
| Procurement Model | In-House Procurement, Outsourced Sequencing Services, Hybrid Procurement |
| Service Delivery Model | Instrument & Consumables Purchase, Full-Service Sequencing, Data Analysis & Interpretation Services |
Next-generation Sequencing Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption and Reimbursement Landscape |
|
| Genomic Data Infrastructure and Bioinformatics Ecosystem |
|
| Precision Medicine Commercialization Opportunities |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the next-generation sequencing market generate?
What is the forecasted size of the next-generation sequencing industry?
How is oncology-driven diagnostic adoption reshaping demand in the next-generation sequencing market?
How are sequencing platform improvements influencing purchasing and replacement cycles?
Why is sequencing the leading workflow in the next-generation sequencing market?
Why is Whole Exome Sequencing the fastest-growing technology segment?
Why is North America the leading region in the next-generation sequencing market?
What is driving next-generation sequencing market growth in Asia Pacific?
What are the prominent companies operating in the next-generation sequencing landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization